We believe that DCs engineered in vitro to recognize and present specific CTAs, such as SP17, AKAP4 and PTTG1, may result in activation of Th1-polarized CTLs capable of overcoming the immunosuppression [31] seen in the NSCLC microenvironment. The gene discussed is PTTG1; the disease is non-small cell lung carcinoma.